Skip to main content
SpringerLink
Log in

An Update on Treatment of Cognitive Impairment Associated with Schizophrenia

  • Chapter
  • First Online:
Cognitive Functioning in Schizophrenia: Leveraging the RDoC Framework

Part of the book series: Current Topics in Behavioral Neurosciences ((CTBN,volume 63))

Abstract

Cognitive impairment associated with schizophrenia (CIAS) is widely regarded as a critically important treatment target for schizophrenia. Despite major efforts and a number of promising findings, we do not yet have an approved drug for CIAS. Similarly, promising cognitive remediation approaches are limited in their ability to help patients achieve real-world functional gains on a wide scale. This article provides an update and critical evaluation of recent treatment development activities for CIAS. First, we provide update on pharmacological approaches, which include a glutamatergic drug that is currently in Phase III trials for CIAS, and discuss factors that may have impacted past efforts to identify efficacious drugs. Second, we review positive findings, limitations, and current trends involving cognitive remediation approaches. Third, we consider newer transdiagnostic approaches aimed at looking beyond, or identifying more homogenous subgroups within, the diagnostic category schizophrenia to advance treatment development. Despite its many challenges, treatment development for CIAS remains a major public health issue and research continues to push forward on several encouraging fronts.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 129.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 169.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 169.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  • Allott K, Van-Der-El K, Bryce S, Parrish EM, McGurk SR, Hetrick S, Bowie CR, Kidd S, Hamilton M, Killackey E, Velligan D (2020) Compensatory interventions for cognitive impairments in psychosis: a systematic review and meta-analysis. Schizophr Bull 46:869–883

    Article  PubMed  PubMed Central  Google Scholar 

  • Balu DT, Coyle JT (2015) The NMDA receptor ‘glycine modulatory site’ in schizophrenia: D-serine, glycine, and beyond. Curr Opin Pharmacol 20:109–115

    Article  CAS  PubMed  Google Scholar 

  • Barch DM (2020) What does it mean to be transdiagnostic and how would we know? Am J Psychiatry 177:370–372

    Article  PubMed  Google Scholar 

  • Barlati S, Deste G, Galluzzo A, Perin AP, Valsecchi P, Turrina C, Vita A (2019) Factors associated with response and resistance to cognitive remediation in schizophrenia: a critical review. Front Pharmacol 9:1542

    Article  PubMed  PubMed Central  Google Scholar 

  • Best MW, Bowie CR (2017) A review of cognitive remediation approaches for schizophrenia: from top-down to bottom-up, brain training to psychotherapy. Expert Rev Neurother 17:713–723

    Article  CAS  PubMed  Google Scholar 

  • Bioque M, Gonzalez-Rodriguez A, Garcia-Rizo C, Cobo J, Monreal JA, Usall J, Soria V, Group P, Labad J (2021) Targeting the microbiome-gut-brain axis for improving cognition in schizophrenia and major mood disorders: a narrative review. Prog Neuro-Psychopharmacol Biol Psychiatry 105:110130

    Article  CAS  Google Scholar 

  • Bleuler E (1950) Dementia praecox or the group of schizophrenias. International Universities Press, New York

    Google Scholar 

  • Bowie CR, Bell MD, Fiszdon JM, Johannesen JK, Lindenmayer JP, McGurk SR, Medalia AA, Penadés R, Saperstein AM, Twamley EW, Ueland T, Wykes T (2020) Cognitive remediation for schizophrenia: an expert working group white paper on core techniques. Schizophr Res 215:49–53

    Article  PubMed  Google Scholar 

  • Brannon S (2017) The difficulties in going from P2 to P3 in CNS trials: red flags from a recent CIS program. In: 13th annual scientific meeting of the Internaltional Society of CNS Clincial Trials, Washington

    Google Scholar 

  • Buchanan RW, Davis M, Goff D, Green MF, Keefe RSE, Leon AC, Nuechterlein KH, Laughren T, Levin R, Stover E, Fenton W, Marder SR (2005) A summary of the FDA-NIMH-MATRICS workshop on clinical trial design for neurocognitive drugs for schizophrenia. Schizophr Bull 31:5–19

    Article  PubMed  Google Scholar 

  • Buchanan RW, Keefe RS, Umbricht D, Green MF, Laughren T, Marder SR (2011) The FDA-NIMH-MATRICS guidelines for clinical trial design of cognitive-enhancing drugs: what do we know 5 years later? Schizophr Bull 37:1209–1217

    Article  PubMed  Google Scholar 

  • Carter CS, Barch DM, Buchanan RW, Bullmore E, Krystal JH, Cohen J, Geyer M, Green M, Nuechterlein KH, Robbins T, Silverstein S, Smith EE, Strauss M, Wykes T, Heinssen R (2008) Identifying cognitive mechanisms targeted for treatment development in schizophrenia: an overview of the first meeting of the cognitive neuroscience treatment research to improve cognition in schizophrenia initiative. Biol Psychiatry 64:4–10

    Article  PubMed  PubMed Central  Google Scholar 

  • Cella M, Price T, Corboy H, Onwumere J, Shergill S, Preti A (2020) Cognitive remediation for inpatients with psychosis: a systematic review and meta-analysis. Psychol Med 50:1062–1076

    Article  PubMed  Google Scholar 

  • Chen Q, Cao T, Li N, Zeng C, Zhang S, Wu X, Zhang B, Cai H (2021) Repurposing of anti-diabetic agents as a new opportunity to alleviate cognitive impairment in neurodegenerative and neuropsychiatric disorders. Front Pharmacol 12:667874

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Ciullo V, Spalletta G, Caltagirone C, Banaj N, Vecchio D, Piras F, Piras F (2021) Transcranial direct current stimulation and cognition in neuropsychiatric disorders: systematic review of the evidence and future directions. Neuroscientist 27:285–309

    Article  CAS  PubMed  Google Scholar 

  • Clementz BA, Sweeney JA, Hamm JP, Ivleva EI, Ethridge LE, Pearlson GD, Keshavan MS, Tamminga CA (2016) Identification of distinct psychosis biotypes using brain-based biomarkers. Am J Psychiatr 173:373–384

    Article  PubMed  Google Scholar 

  • Cotter J, Barnett JH, Granger K (2019) The use of cognitive screening in pharmacotherapy trials for cognitive impairment associated with schizophrenia. Front Psych 10:648

    Article  Google Scholar 

  • Cummings JL, Morstorf T, Zhong K (2014) Alzheimer’s disease drug development pipeline: few candidates, frequent failures. Alzheimers Res Ther 6:1–7

    Article  Google Scholar 

  • Cummings J, Lee G, Ritter A, Sabbagh M, Zhong K (2020) Alzheimer's disease drug development pipeline: 2020. Alzheimers Dement (N Y) 6:e12050

    PubMed  Google Scholar 

  • Cuthbert BN (2014) The RDoC framework: facilitating transition from ICD/DSM to dimensional approaches that integrate neuroscience and psychopathology. World Psychiatry 13:28–35

    Article  PubMed  PubMed Central  Google Scholar 

  • Cuthbert BN, Morris SE (2021) Evolving concepts of the schizophrenia spectrum: a research domain criteria perspective. Front Psych 12:641319

    Article  Google Scholar 

  • Davis MC, Horan WP, Marder SR (2014) Psychopharmacology of the negative symptoms: current status and prospects for progress. Eur Neuropsychopharmacol 24:788–799

    Article  CAS  PubMed  Google Scholar 

  • Dickerson F, Origoni A, Katsafanas E, Squire A, Newman T, Fahey J, Xiao JC, Stallings C, Goga J, Khushalani S, Yolken R (2021) Randomized controlled trial of an adjunctive sulforaphane nutraceutical in schizophrenia. Schizophr Res 231:142–144

    Article  CAS  PubMed  Google Scholar 

  • Fleischhacker WW, Podhorna J, Groschl M, Hake S, Zhao Y, Huang S, Keefe RSE, Desch M, Brenner R, Walling DP, Mantero-Atienza E, Nakagome K, Pollentier S (2021) Efficacy and safety of the novel glycine transporter inhibitor BI 425809 once daily in patients with schizophrenia: a double-blind, randomised, placebo-controlled phase 2 study. Lancet Psychiatry 8:191–201

    Article  PubMed  Google Scholar 

  • Georgiades A, Davis VG, Atkins AS, Khan A, Walker TW, Loebel A, Haig G, Hilt DC, Dunayevich E, Umbricht D, Sand M, Keefe RSE (2017) Psychometric characteristics of the MATRICS consensus cognitive battery in a large pooled cohort of stable schizophrenia patients. Schizophr Res 190:172–179

    Article  PubMed  Google Scholar 

  • Gold JM (2004) Cognitive deficits as treatment targets in schizophrenia. Schizophr Res 72:21–28

    Article  PubMed  Google Scholar 

  • Goodkind M, Eickhoff SB, Oathes DJ, Jiang Y, Chang A, Jones-Hagata LB, Ortega BN, Zaiko YV, Roach EL, Korgaonkar MS, Grieve SM, Galatzer-Levy I, Fox PT, Etkin A (2015) Identification of a common neurobiological substrate for mental illness. JAMA Psychiat 72:305–315

    Article  Google Scholar 

  • Granger K, Cotter J, Baker E, Evenden J, Barnett J, Sand M (2018) Exploring participant-level trajectories of cognitive performance among patients with schizophrenia in a multi-national trial. Schizophr Bull 44:S353–S353

    Article  PubMed Central  Google Scholar 

  • Green MF, Nuechterlein KH, Gold JM, Barch DM, Cohen J, Essock S, Fenton WS, Frese F, Goldberg TE, Heaton RK, Keefe RSE, Kern RS, Kraemer H, Stover E, Weinberger DR, Zalcman S, Marder SR (2004) Approaching a consensus cognitive battery for clinical trials in schizophrenia: the NIMH-MATRICS conference to select cognitive domains and test criteria. Biol Psychiatry 56:301–307

    Article  PubMed  Google Scholar 

  • Green MF, Harris JG, Nuechterlein KH (2014) The MATRICS consensus cognitive battery: what we know 6 years later. Am J Psychiatry 171:1151–1154

    Article  PubMed  Google Scholar 

  • Green MF, Horan WP, Lee J (2019) Nonsocial and social cognition in schizophrenia: current evidence and future directions. World Psychiatry 18:146–161

    Article  PubMed  PubMed Central  Google Scholar 

  • Harvey PD, Bowie CR (2012) Cognitive enhancement in schizophrenia. Pharmacological and cognitive remediation approaches. Psychiatr Clin N Am 35:683–698

    Article  Google Scholar 

  • Harvey PD, McGurk SR, Mahncke H, Wykes T (2018) Controversies in computerized cognitive training. Biol Psychiatr Cogn Neurosci Neuroimaging 3:907–915

    Google Scholar 

  • Heaton R, Paulsen JS, McAdams LA, Kuck J, Zisook S, Braff D, Harris J, Jeste DV (1994) Neuropsychological deficits in schizophrenics: relationship to age, chronicity, and dementia. Arch Gen Psychiatry 51:469–476

    Article  CAS  PubMed  Google Scholar 

  • Heinrichs RW, Zakzanis KK (1998) Neurocognitive deficit in schizophrenia: a quantitative review of the evidence. Neuropsychology 12:426–445

    Article  CAS  PubMed  Google Scholar 

  • Hochberger WC, Joshi YB, Thomas ML, Zhang W, Bismark AW, Treichler EBH, Tarasenko M, Nungaray J, Sprock J, Cardoso L, Swerdlow N, Light GA (2019) Neurophysiologic measures of target engagement predict response to auditory-based cognitive training in treatment refractory schizophrenia. Neuropsychopharmacology 44:606–612

    Article  CAS  PubMed  Google Scholar 

  • Hong J, Bang M (2020) Anti-inflammatory strategies for schizophrenia: a review of evidence for therapeutic applications and drug repurposing. Clin Psychopharmacol Neurosci 18:10–24

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Hufford MR, Davis VG, Hilt D, Dgetluck N, Geffen Y, Loebel A, Haig G, Santarelli L, Keefe RS (2014) Circadian rhythms in cognitive functioning among patients with schizophrenia: impact on signal detection in clinical trials of potential pro-cognitive therapies. Schizophr Res 159:205–210

    Article  PubMed  Google Scholar 

  • Insel T, Cuthbert B, Garvey M, Heinssen R, Pine DS, Quinn K, Sanislow C, Wang P (2010) Research domain criteria (RDoC): toward a new classification framework for research on mental disorders. Am J Psychiatr 167:748–751

    Article  PubMed  Google Scholar 

  • Javitt DC (2009) Glycine transport inhibitors for the treatment of schizophrenia: symptom and disease modification. Curr Opin Drug Discov Devel 12:468–478

    CAS  PubMed  Google Scholar 

  • Joshi YB, Thomas ML, Braff DL, Green MF, Gur RC, Gur RE, Nuechterlein KH, Stone WS, Greenwood TA, Lazzeroni LC, MacDonald LR, Molina JL, Nungaray JA, Radant AD, Silverman JM, Sprock J, Sugar CA, Tsuang DW, Tsuang MT, Turetsky BI, Swerdlow NR, Light GA (2021) Anticholinergic medication burden-associated cognitive impairment in schizophrenia. Am J Psychiatry 178:838–847

    Article  PubMed  PubMed Central  Google Scholar 

  • Kahn RS (2020) On the origins of schizophrenia. Am J Psychiatry 177:291–297

    Article  PubMed  Google Scholar 

  • Kambeitz-Ilankovic L, Betz LT, Dominke C, Haas SS, Subramaniam K, Fisher M, Vinogradov S, Koutsouleris N, Kambeitz J (2019) Multi-outcome meta-analysis (MOMA) of cognitive remediation in schizophrenia: revisiting the relevance of human coaching and elucidating interplay between multiple outcomes. Neurosci Biobehav Rev 107:828–845

    Article  PubMed  PubMed Central  Google Scholar 

  • Keefe RSE (2019) Why are there no approved treatments for cognitive impairment in schizophrenia? World Psychiatry 18:167–168

    Article  PubMed  PubMed Central  Google Scholar 

  • Keefe RSE (2021) Where do we cut the bell-shaped curve of CIAS? Schizophenia Res 228:633–634

    Article  Google Scholar 

  • Keefe RS, Harvey PD (2008) Implementation considerations for multisite clinical trials with cognitive neuroscience tasks. Schizophr Bull 34:656–663

    Article  PubMed  PubMed Central  Google Scholar 

  • Keefe RS, Eesley CE, Poe MP (2005) Defining a cognitive function decrement in schizophrenia. Biol Psychiatry 57:688–691

    Article  PubMed  Google Scholar 

  • Keefe RS, Fox KH, Harvey PD, Cucchiaro J, Siu C, Loebel A (2011) Characteristics of the MATRICS consensus cognitive battery in a 29-site antipsychotic schizophrenia clinical trial. Schizophr Res 125:161–168

    Article  PubMed  Google Scholar 

  • Keefe RS, Buchanan RW, Marder SR, Schooler NR, Dugar A, Zivkov M, Stewart M (2013) Clinical trials of potential cognitive-enhancing drugs in schizophrenia: what have we learned so far? Schizophr Bull 39:417–435

    Article  PubMed  Google Scholar 

  • Keefe RS, Meltzer HA, Dgetluck N, Gawryl M, Koenig G, Moebius HJ, Lombardo I, Hilt DC (2015) Randomized, double-blind, placebo-controlled study of encenicline, an alpha7 nicotinic acetylcholine receptor agonist, as a treatment for cognitive impairment in schizophrenia. Neuropsychopharmacology 40:3053–3060

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Keefe RS, Haig GM, Marder SR, Harvey PD, Dunayevich E, Medalia A, Davidson M, Lombardo I, Bowie CR, Buchanan RW, Bugarski-Kirola D, Carpenter WT, Csernansky JT, Dago PL, Durand DM, Frese FJ, Goff DC, Gold JM, Hooker CI, Kopelowicz A, Loebel A, McGurk SR, Opler LA, Pinkham AE, Stern RG (2016) Report on ISCTM consensus meeting on clinical assessment of response to treatment of cognitive impairment in schizophrenia. Schizophr Bull 42:19–33

    PubMed  Google Scholar 

  • Keefe RSE, Davis VG, Harvey PD, Atkins AS, Haig GM, Hagino O, Marder S, Hilt DC, Umbricht D (2017) Placebo response and practice effects in schizophrenia cognition trials. JAMA Psychiat 74:807–814

    Article  Google Scholar 

  • Keefe RSE, Harvey PD, Khan A, Saoud JB, Staner C, Davidson M, Luthringer R (2018) Cognitive effects of MIN-101 in patients with schizophrenia and negative symptoms: results from a randomized controlled trial. J Clin Psychiatry 79(3):17m11753

    Article  PubMed  Google Scholar 

  • Kirkpatrick B, Fenton WS, Carpenter WT Jr, Marder SR (2006) The NIMH-MATRICS consensus statement on negative symptoms. Schizophr Bull 32:214–219

    Article  PubMed  PubMed Central  Google Scholar 

  • Kotov R, Krueger RF, Watson D, Achenbach TM, Althoff RR, Bagby RM, Brown TA, Carpenter WT, Caspi A, Clark LA, Eaton NR, Forbes MK, Forbush KT, Goldberg D, Hasin D, Hyman SE, Ivanova MY, Lynam DR, Markon K, Miller JD, Moffitt TE, Morey LC, Mullins-Sweatt SN, Ormel J, Patrick CJ, Regier DA, Rescorla L, Ruggero CJ, Samuel DB, Sellbom M, Simms LJ, Skodol AE, Slade T, South SC, Tackett JL, Waldman ID, Waszczuk MA, Widiger TA, Wright AGC, Zimmerman M (2017) The hierarchical taxonomy of psychopathology (HiTOP): a dimensional alternative to traditional nosologies. J Abnorm Psychol 126:454–477

    Article  PubMed  Google Scholar 

  • Lee J, Altshuler L, Glahn DC, Miklowitz DJ, Ochsner K, Green MF (2013) Social and nonsocial cognition in bipolar disorder and schizophrenia: relative levels of impairment. Am J Psychiatr 170:334–341

    Article  PubMed  Google Scholar 

  • Lejeune JA, Northrop A, Kurtz MM (2021) A meta-analysis of cognitive remediation for schizophrenia: efficacy and the role of participant and treatment factors. Schizophr Bull 47:997–1006

    Article  PubMed  PubMed Central  Google Scholar 

  • Levkovitz Y, Mendlovich S, Riwkes S, Braw Y, Levkovitch-Verbin H, Gal G, Fennig S, Treves I, Kron S (2010) A double-blind, randomized study of minocycline for the treatment of negative and cognitive symptoms in early-phase schizophrenia. J Clin Psychiatry 71:138–149

    Article  CAS  PubMed  Google Scholar 

  • Marder SR (2006) The NIMH-MATRICS project for developing cognition-enhancing agents for schizophrenia. Dialogues Clin Neurosci 8:109–113

    Article  PubMed  PubMed Central  Google Scholar 

  • Marder SR, Fenton W (2004) Measurement and treatment research to improve cognition in schizophrenia: NIMH MATRICS initiative to support the development of agents for improving cognition in schizophrenia. Schizophr Res 72:5–9

    Article  PubMed  Google Scholar 

  • Marder SR, Laughren T, Romano SJ (2017) Why are innovative drugs failing in phase III? Am J Psychiatry 174:829–831

    Article  PubMed  Google Scholar 

  • Marx W, Skvarc DR, Mohebbi M, Walker AJ, Meehan A, Turner A, Baker A, Dodd S, Cotton SM, Scott JG, Kavanagh BE, Ashton MM, Brown E, McGrath JJ, Berk M, Dean OM (2021) The effect of adjunctive mangosteen pericarp on cognition in people with schizophrenia: secondary analysis of a randomized controlled trial. Front Psych 12:626486

    Article  Google Scholar 

  • McClure MM, Graff F, Triebwasser J, Perez-Rodriguez M, Rosell DR, Koenigsberg H, Hazlett EA, Siever LJ, Harvey PD, New AS (2019) Guanfacine augmentation of a combined intervention of computerized cognitive remediation therapy and social skills training for schizotypal personality disorder. Am J Psychiatry 176:307–314

    Article  PubMed  PubMed Central  Google Scholar 

  • McTeague LM, Huemer J, Carreon DM, Jiang Y, Eickhoff SB, Etkin A (2017) Identification of common neural circuit disruptions in cognitive control across psychiatric disorders. Am J Psychiatry 174:676–685

    Article  PubMed  PubMed Central  Google Scholar 

  • McTeague LM, Rosenberg BM, Lopez JW, Carreon DM, Huemer J, Jiang Y, Chick CF, Eickhoff SB, Etkin A (2020) Identification of common neural circuit disruptions in emotional processing across psychiatric disorders. Am J Psychiatry 177:411–421

    Article  PubMed  PubMed Central  Google Scholar 

  • Medalia A, Saperstein AM, Hansen MC, Lee S (2018) Personalised treatment for cognitive dysfunction in individuals with schizophrenia spectrum disorders. Neuropsychol Rehabil 28:602–613

    Article  PubMed  Google Scholar 

  • Medalia A, Saperstein AM, Stefancic A, Meyler S, Styke S, Qian M, Liu J, Cabassa LJ (2021) Feasibility and acceptability of remotely accessed cognitive remediation for schizophrenia in public health settings. Psychiatry Res 301:113956

    Article  PubMed  PubMed Central  Google Scholar 

  • Mollon J, Reichenberg A (2018) Cognitive development prior to onset of psychosis. Psychol Med 48:392–403

    Article  CAS  PubMed  Google Scholar 

  • Nuechterlein KH, Green MF, Kern RS, Baade LE, Barch DM, Cohen JD, Essock S, Fenton WS, Frese FJ 3rd, Gold JM, Goldberg T, Heaton RK, Keefe RS, Kraemer H, Mesholam-Gately R, Seidman LJ, Stover E, Weinberger DR, Young AS, Zalcman S, Marder SR (2008) The MATRICS consensus cognitive battery, part 1: test selection, reliability, and validity. Am J Psychiatry 165:203–213

    Article  PubMed  Google Scholar 

  • Prikken M, Konings MJ, Lei WU, Begemann MJH, Sommer IEC (2019) The efficacy of computerized cognitive drill and practice training for patients with a schizophrenia-spectrum disorder: a meta-analysis. Schizophr Res 204:368–374

    Article  PubMed  Google Scholar 

  • Recio-Barbero M, Segarra R, Zabala A, Gonzalez-Fraile E, Gonzalez-Pinto A, Ballesteros J (2021) Cognitive enhancers in schizophrenia: a systematic review and meta-analysis of alpha-7 nicotinic acetylcholine receptor agonists for cognitive deficits and negative symptoms. Front Psych 12:631589

    Article  Google Scholar 

  • Reser MP, Slikboer R, Rossell SL (2019) A systematic review of factors that influence the efficacy of cognitive remediation therapy in schizophrenia. Aust N Z J Psychiatry 53:624–641

    Article  PubMed  Google Scholar 

  • Saperstein AM, Kurtz MM (2013) Current trends in the empirical study of cognitive remediation for schizophrenia. Can J Psychiatr 58:311–318

    Article  Google Scholar 

  • Saperstein AM, Choi CJ, Jahshan C, Lynch DA, Wall M, Green MF, Medalia A (2021) Predicting response to cognitive training for schizophrenia using results from two studies with different outcomes. Schizophr Res 231:61–66

    Article  PubMed  PubMed Central  Google Scholar 

  • Seccomandi B, Agbedjro D, Bell M, Keefe RSE, Keshavan M, Galderisi S, Fiszdon J, Mucci A, Cavallaro R, Ojeda N, Peña J, Müller D, Roder V, Wykes T, Cella M (2021a) Exploring the role of age as a moderator of cognitive remediation for people with schizophrenia. Schizophr Res 228:29–35

    Article  PubMed  Google Scholar 

  • Seccomandi B, Agbedjro D, Bell M, Keefe RSE, Keshavan M, Galderisi S, Fiszdon J, Mucci A, Cavallaro R, Bechi M, Ojeda N, Peña J, Wykes T, Cella M (2021b) Can IQ moderate the response to cognitive remediation in people with schizophrenia? J Psychiatr Res 133:38–45

    Article  PubMed  Google Scholar 

  • Singer P, Dubroqua S, Yee BK (2015) Inhibition of glycine transporter 1: the yellow brick road to new schizophrenia therapy? Curr Pharm Des 21:3771–3787

    Article  CAS  PubMed  Google Scholar 

  • Sinkeviciute I, Begemann M, Prikken M, Oranje B, Johnsen E, Lei WU, Hugdahl K, Kroken RA, Rau C, Jacobs JD, Mattaroccia S, Sommer IE (2018) Efficacy of different types of cognitive enhancers for patients with schizophrenia: a meta-analysis. NPJ Schizophr 4:22

    Article  PubMed  PubMed Central  Google Scholar 

  • Smith MJ, Fleming MF, Wright MA, Roberts AG, Humm LB, Olsen D, Bell MD (2015) Virtual reality job interview training and 6-month employment outcomes for individuals with schizophrenia seeking employment. Schizophr Res 166:86–91

    Article  PubMed  PubMed Central  Google Scholar 

  • Smucny J, Barch DM, Gold JM, Strauss ME, MacDonald AW 3rd, Boudewyn MA, Ragland JD, Silverstein SM, Carter CS (2019) Cross-diagnostic analysis of cognitive control in mental illness: insights from the CNTRACS consortium. Schizophr Res 208:377–383

    Article  PubMed  PubMed Central  Google Scholar 

  • Tamminga CA, Pearlson GD, Stan AD, Gibbons RD, Padmanabhan J, Keshavan M, Clementz BA (2017) Strategies for advancing disease definition using biomarkers and genetics: the bipolar and schizophrenia network for intermediate phenotypes. Biol Psychiatr Cogn Neurosci Neuroimaging 2:20–27

    Google Scholar 

  • Thomas DW, Burns J, Audette J, Carroll A, Dow-Hygelund C, Hay M (2016) Clinical development success rates 2006–2015. Biotechnology Innovation Organization, Washington

    Google Scholar 

  • Umbricht D, Keefe RS, Murray S, Lowe DA, Porter R, Garibaldi G, Santarelli L (2014) A randomized, placebo-controlled study investigating the nicotinic alpha7 agonist, RG3487, for cognitive deficits in schizophrenia. Neuropsychopharmacology 39:1568–1577

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Van Duin D, De Winter L, Oud M, Kroon H, Veling W, Van Weeghel J (2019) The effect of rehabilitation combined with cognitive remediation on functioning in persons with severe mental illness: systematic review and meta-analysis. Psychol Med 49:1414–1425

    Article  PubMed  Google Scholar 

  • Vita A, Barlati S, Ceraso A, Nibbio G, Ariu C, Deste G, Wykes T (2021) Effectiveness, core elements, and moderators of response of cognitive remediation for schizophrenia: a systematic review and meta-analysis of randomized clinical trials. JAMA Psychiat 78:848–858

    Article  Google Scholar 

  • Wykes T, Huddy V, Cellard C, McGurk SR, Czobor P (2011) A meta-analysis of cognitive remediation for schizophrenia: methodology and effect sizes. Am J Psychiatr 168:472–485

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. WCG VeraSci, Durham, NC, USA

    William P. Horan

  2. Department of Psychiatry and Biobehavioral Sciences, David Geffen School of Medicine, University of California, Los Angeles, Los Angeles, CA, USA

    William P. Horan, Lauren T. Catalano & Michael F. Green

  3. Veterans Affairs Greater Los Angeles Healthcare System, Los Angeles, CA, USA

    Lauren T. Catalano & Michael F. Green

Authors
  1. William P. Horan
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Lauren T. Catalano
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Michael F. Green
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to William P. Horan .

Editor information

Editors and Affiliations

  1. Departments of Psychological and Brain Sciences, Psychiatry, and Radiology, Washington University, Saint Louis, MO, USA

    Deanna M. Barch

  2. Department of Psychiatry, University of California San Diego, La Jolla, CA, USA

    Jared W. Young

Ethics declarations

WPH is a full-time employee at WCG VeraSci. MFG has been a paid consultant for Biogen, Otsuka, and Teva. MFG is also an officer in a non-profit organization, MATRICS Assessment, Inc., but receives no financial compensation. LTC has no disclosures.

Rights and permissions

Reprints and permissions

Copyright information

© 2022 The Author(s), under exclusive license to Springer Nature Switzerland AG

About this chapter

Check for updates. Verify currency and authenticity via CrossMark

Cite this chapter

Horan, W.P., Catalano, L.T., Green, M.F. (2022). An Update on Treatment of Cognitive Impairment Associated with Schizophrenia. In: Barch, D.M., Young, J.W. (eds) Cognitive Functioning in Schizophrenia: Leveraging the RDoC Framework. Current Topics in Behavioral Neurosciences, vol 63. Springer, Cham. https://doi.org/10.1007/7854_2022_382

Download citation

Publish with us

Policies and ethics

Search

Navigation